Aridis Pharmaceuticals ARDS Stock
Aridis Pharmaceuticals Price Chart
Aridis Pharmaceuticals ARDS Financial and Trading Overview
Aridis Pharmaceuticals stock price | 0.0001 USD |
Previous Close | 0.27 USD |
Open | 0.26 USD |
Bid | 0 USD x 1400 |
Ask | 0 USD x 800 |
Day's Range | 0.26 - 0.27 USD |
52 Week Range | 0.15 - 2.77 USD |
Volume | 484.7K USD |
Avg. Volume | 3.47M USD |
Market Cap | 9.74M USD |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.16 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10 USD |
ARDS Valuation Measures
Enterprise Value | 9.78M USD |
Trailing P/E | N/A |
Forward P/E | 1.038077 |
PEG Ratio (5 yr expected) | -0.01 |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | N/A |
Trading Information
Aridis Pharmaceuticals Stock Price History
Beta (5Y Monthly) | N/A |
52-Week Change | -80.85% |
S&P500 52-Week Change | 20.43% |
52 Week High | 2.77 USD |
52 Week Low | 0.15 USD |
50-Day Moving Average | 0.23 USD |
200-Day Moving Average | 0.75 USD |
ARDS Share Statistics
Avg. Volume (3 month) | 3.47M USD |
Avg. Daily Volume (10-Days) | 1.27M USD |
Shares Outstanding | 36.08M |
Float | N/A |
Short Ratio | 0.05 |
% Held by Insiders | 31.53% |
% Held by Institutions | 11.60% |
Shares Short | 439.68K |
Short % of Float | 1.48% |
Short % of Shares Outstanding | 1.22% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | N/A |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | 0.17 USD |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | -22605000 USD |
EBITDA | N/A |
Net Income Avi to Common (ttm) | N/A |
Diluted EPS (ttm) | -1.38 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | N/A |
Total Cash Per Share (mrq) | N/A |
Total Debt (mrq) | N/A |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | N/A |
Book Value Per Share (mrq) | -0.896 |
Cash Flow Statement
Operating Cash Flow (ttm) | N/A |
Levered Free Cash Flow (ttm) | N/A |
Profile of Aridis Pharmaceuticals
Country | United States |
State | CA |
City | Los Gatos |
Address | 983 University Avenue |
ZIP | 95032 |
Phone | 408 385 1742 |
Website | https://www.aridispharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 37 |
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.
Q&A For Aridis Pharmaceuticals Stock
What is a current ARDS stock price?
Aridis Pharmaceuticals ARDS stock price today per share is 0.0001 USD.
How to purchase Aridis Pharmaceuticals stock?
You can buy ARDS shares on the OTC Markets EXMKT exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Aridis Pharmaceuticals?
The stock symbol or ticker of Aridis Pharmaceuticals is ARDS.
Which industry does the Aridis Pharmaceuticals company belong to?
The Aridis Pharmaceuticals industry is Biotechnology.
How many shares does Aridis Pharmaceuticals have in circulation?
The max supply of Aridis Pharmaceuticals shares is 44.57M.
What is Aridis Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Aridis Pharmaceuticals PE Ratio is now.
What was Aridis Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Aridis Pharmaceuticals EPS is -0.16 USD over the trailing 12 months.
Which sector does the Aridis Pharmaceuticals company belong to?
The Aridis Pharmaceuticals sector is Healthcare.
Aridis Pharmaceuticals ARDS included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15603.26 USD — |
+0.1
|
10.08B USD — | 14784.03 USD — | 16292.28 USD — | — - | 10.08B USD — |
NASDAQ Capital Market Composite RCMP | 91.92 USD — |
-0.27
|
— — | 86.91 USD — | 95.14 USD — | — - | — — |
NASDAQ HealthCare IXHC | 865.57 USD — |
-0.49
|
— — | 828.4 USD — | 890 USD — | — - | — — |
- {{ link.label }} {{link}}